&nbsp;

Jan 2026

Drug

pembrolizumab

Other Name(s): Keytruda®

Quick Link(s):

Sep 2025

Drug

blinatumomab

Other Name(s): Blincyto®

Quick Link(s):

Nov 2025

Drug

siltuximab

Other Name(s): Sylvant®

Quick Link(s):

Mar 2025

Drug

palbociclib

Other Name(s): Ibrance™

Quick Link(s):

Oct 2025

Drug

venetoclax

Other Name(s): Venclexta®

Quick Link(s):

Aug 2025

Drug

midostaurin

Other Name(s): Rydapt®

Quick Link(s):

Jun 2025

Regimen

CYCLDOCE; CYCLDOCE+TRAS

Cancer Type:

Breast

Intent: Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph, Patient Info Sheet (CYCLDOCE)

Jan 2024

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

daSAtinib - Ph+ CML in the chronic phase, with specific criteria

Exceptional Access Program

daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria

Drugs Used:

daSATinib

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DCRB

Cancer Type:

Sarcoma,

Soft Tissue,

Skin,

Melanoma

Intent: Palliative

Drugs Used:

dacarbazine

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

EXEM

Cancer Type:

Breast

Intent: Adjuvant

Funding:

ODB - General Benefit

exemestane

Drugs Used:

exemestane

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

EXEM

Cancer Type:

Breast,

Gynecologic,

Endometrial

Intent: Palliative

Funding:

ODB - General Benefit

exemestane

Drugs Used:

exemestane